BackI-Mab Overview

I-Mab Current Cash

Latest current cash for IMAB: $170M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$165.40M
↑ 8.85% YoYΔ $13.44M vs prior year quarter

Peer average

Loading

I-Mab Current Cash History

Loading

I-Mab vs. peers: Current Cash Comparison

Loading

I-Mab Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

I-Mab (IMAB) FAQ

I-Mab (IMAB) currently reports a current cash of $170M as of June 2025. That compares with $150M in the prior-year period — up 8.8% year over year. Use the charts on this page to explore I-Mab's current cash history and peer comparisons.

I-Mab's current cash increased from $150M to $170M — a 8.8% year-over-year increase (period ending June 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

I-Mab reported $170M in current cash as of June 2025. That compares with $150M in the prior-year period — up 8.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $170M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for I-Mab, and consider following IMAB for alerts when major investors trade the stock.

I-Mab is classified in the Healthcare sector. On current cash, it currently shows $170M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMAB with unrelated industries.